This presentation explores the role of neuroimaging biomarkers in the early detection and diagnosis of Alzheimer's disease. We discuss advanced imaging techniques such as PET-CT, MRI, and amyloid imaging, and their utility in identifying preclinical and prodromal stages of Alzheimer's disease.

This presentation provides an overview of recent advancements in deep brain stimulation (DBS) therapy for Parkinson's disease. We discuss the latest electrode designs, surgical techniques, and programming strategies aimed at optimizing therapeutic outcomes and minimizing adverse effects in patients with Parkinson's disease.

This presentation provides an overview of recent advancements in deep brain stimulation (DBS) therapy for Parkinson's disease. We discuss the latest electrode designs, surgical techniques, and programming strategies aimed at optimizing therapeutic outcomes and minimizing adverse effects in patients with Parkinson's disease.

This presentation provides an overview of precision medicine approaches in the management of lung cancer, emphasizing targeted therapies and biomarker-driven treatment strategies. We discuss the role of genomic profiling, molecular diagnostics, and personalized medicine in optimizing patient outcomes and treatment efficacy.

This presentation highlights recent advancements in immunotherapy for melanoma, focusing on novel treatment approaches and combination strategies. We discuss the mechanisms of action of immunotherapeutic agents, clinical trial data, and emerging biomarkers for predicting treatment response.

This presentation highlights recent advancements in immunotherapy for melanoma, focusing on novel treatment approaches and combination strategies. We discuss the mechanisms of action of immunotherapeutic agents, clinical trial data, and emerging biomarkers for predicting treatment response.

This presentation explores the role of the tumor microenvironment in breast cancer progression and metastasis. We discuss novel therapeutic strategies targeting the tumor microenvironment, including immune checkpoint inhibitors and stromal-targeted therapies, and their potential impact on patient outcomes.